Clinical Trial Update: The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

View source ↗

Summary

A real-world study is being conducted to determine the incidence and risk factors of CNS adverse events in ALK-positive advanced non-small cell lung cancer pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: ALK, NSCLC | Status: NOT_YET_RECRUITING